Durable responses to avelumab in patients with Merkel cell carcinoma

Dr Kaufman speaks with ecancer at AACR 2017 about the effectiveness of anti-PD-L1 avelumab in treating Merkel cell carcinoma (MCC) in patients who had been previously treated with chemotherapy.

He describes results from 88 patients with metastatic disease, who at 6 months follow-up had 31% response, and 33% response at 1 year.